Advertisement
Editorial| Volume 135, ISSUE 4, P447-448, April 2004

Editorial review of “Malignant progression from C-cell hyperplasia to medullary thyroid carcinoma in 167 RET germline mutations”

  • Scott Wilhelm
    Correspondence
    Reprint requests: Richard A. Prinz, MD, Helen Shedd Keith Professor & Chairman, Department of General Surgery, Rush-Presbyterian–St. Luke's Medical, 1653 W Congress Pkwy, 7th Floor Jelke, Chicago, IL 60612-3833.
    Affiliations
    From the Department of General Surgery, Rush-Presbyterian–St. Luke's Medical, Chicago, Ill USA
    Search for articles by this author
  • Richard A. Prinz
    Affiliations
    From the Department of General Surgery, Rush-Presbyterian–St. Luke's Medical, Chicago, Ill USA
    Search for articles by this author
      The discovery of the ret proto-oncogene in 1993 demonstrates the influence of genetic testing on clinical practice. A germline mutation in the RET gene, which is located on chromosome 10, leads to an alteration of the transmembrane tyrosine kinase receptor, which is expressed primarily in neuroendocrine and neural cells. A patient with this genotype phenotypically can express several disease states that include medullary thyroid cancer (MTC), hyperparathyroidism, pheochromocytoma, and, less commonly, Hirschsprung's disease and cutaneous lichen amyloidosis. The expression of “inheritable” MTC occurs in the context of multiple endocrine neoplasia (MEN) II A, MEN II B, and familial MTC. The eventual neoplastic transformation of normal thyroid parafollicular C-cells to C-cell hyperplasia (CCH), and MTC occurs with 100% penetrance in patients with a germline mutation in the RET gene. This definitive pattern of expression should allow for prophylactic surgical intervention before the formation of MTC. The issue is when to perform thyroidectomy in patients with this tumor, because the procedure is technically more demanding and prone to complications the younger the patient, but the risk of tumor transformation or dissemination increases while waiting.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Machens A.
        • Holzhausen H.J.
        • Thanh P.N.
        • Dralle H.
        Malignant progression from C-cell hyperplasia to medullary thyroid carcinoma in 167 carriers of RET germline mutations.
        Surgery. 2003; 134: 425-431
        • Yip L.
        • Cote G.J.
        • Shapiro S.E.
        • Ayers G.D.
        • Herzog C.E.
        • Sellin R.V.
        • et al.
        Multiple endocrine neoplasia type 2: evaluation of the genotype-phenotype relationship.
        Arch Surg. 2003; 138: 409-416
        • Eng C.
        • Clayton D.
        • Schuffenecker I.
        • Lenoir G.
        • Cote G.
        • Gagel R.F.
        • et al.
        The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2: international RET mutation consortium analysis.
        JAMA. 1996; 276: 1575-1579